Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy

Pakistan Journal of Biological Sciences

Volumn 15, Issue 2, 2012, Pages 68-77

  Saleh, Dina Ahmed Amin ^a   Ismail, Mona Ahmed ^a   Ibrahim, Ayman Mohamed ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Dyslipidemia; Epilepsy; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ANTICONVULSIVE AGENT;

ABDOMEN; ADOLESCENT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CASE CONTROL STUDY; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; EPILEPSY; FATTY LIVER; HISTOLOGY; HUMAN; INSULIN RESISTANCE; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ABDOMEN; ADOLESCENT; ANTICONVULSANTS; ATHEROSCLEROSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; EPILEPSY; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84857755330     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2012.68.77     Document Type: Article

References (77)

1. Abdel-Wahab, B.A. and M.E. Metwally, 2011. Ginkgo biloba enhances the anticonvulsant and neuroprotective effects of sodium valproate against kainic acid-induced seizures in mice. J. Pharmacol. Toxicol, 6: 679-690.
2. Ahmad, M., 2011. Epilepsy: Stigma and management. Curr. Res. Neurosci., 1: 1-14.
3. Akbar, D.H. and AH. Kawther, 2006. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know? Med. Sci. Monit, 12: RA23-RA26.
4. Almenabbawy, K.M., S.I. Helal, S.T. Zaki, O.M. Said, M.M. Salam, M.M. Abdelmoneim and L.M. Aboismaiel, 2009. Is balanced diet has effect on epileptics? J. Med. Sci., 9: 234-239.
5. Angulo, P., 2002. Non-alcoholic fatty liver disease. New Engl. J. Med., 346: 1221-1231.
6. Ansari, J.A., M. Sayyed and F. Sayeed, 2011. Management of non alcoholic fatty liver diseases and their complications. Int. J. Pharmacol., 7: 579-588.
7. 2. Clin. Chem., 29: 2026-2030.
8. Bedogni, G., S. Bellentani, L. Miglioli, F. Masutti, M. Passalacqua, A. Castiglione and C. Tiribelli, 2006. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. B.M.C. Gastroenterol., 6: 33-33.
9. Carl, A., E.R. Ashwood and D.E. Bruns, 2006. Lipids, Lipoproteins, Apolipoproteins and other Cardiovascular Risk Factors. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Carl, A., E.R. Ashwood and D.E. Bruns (Eds.). Saunders, Philadelphia, USA., Pages: 2448.
10. Chan, D.C., PH. Barrett and G.F. Watts, 2004a. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Clin Sci., 107: 221-232.
11. Chan, D.F., A.M. Li, W.C. Chu, M.H. Chan and E.M. Wong et al, 2004b. Hepatic steatosis in obese Chinese children. Int. J. Obes. Relat. Metab. Disord., 28: 1257-1263.
12. Commission on Classification and Terminology of the International League Against Epilepsy, 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia, 30: 389-399.
13. Cook, S., M. Weitzman, P. Auinger, M. Nguyen and W.H. Dietz, 2003. Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third national health and nutrition examination survey, 1988-1994. Arch. Paediatr. Adolesc. Med., 157:821-827.
14. Cotrim, H.P., R. Parana, E. Braga and L. Lyra, 2000. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Natural history. Am. J. Gastroenterol., 95: 3018-3019.
15. Daniel, W.W., 1995. Biostatistics: A Foundation for Analysis in the Health Sciences. 6th Edn, John Wiley and Sons Inc., New York.
16. Day, CP., 2002. Non-alcoholic steatohepatitis: Where are we now and where are we going?. Gut, 50: 585-588.
17. De Onis, M., A.W. Onyango, E. Borghi, A. Siyam, C. Nishida and J. Siekmann, 2007. Development of a WHO growth reference for school-aged children and adolescents. Bull. World Health Org., 85: 660-667.
18. Demircioolu, S., A. Soylu and E. Dink, 2000. Carbamazepine and valproic acid: Effects on the serum lipids and liver functions in children. Pediatr. Neurol, 23: 142-146.
19. Desouky, A.M., M. Raafat, A.A. Metwaly, A. El-Shamaa and E. Abdallah, 2007. Arterial compliance, renal, cardiac, endocrine and metabolic disorders as a predictors of hypertension syndrome. J. Med. Sci., 7: 503-515.
20. Dietschy, J.M., L.E. Weeks and J.J. Delento, 1976. Enzymatic assessment of free and estrified cholesterol levels using the oxygen electrode in a modified glucose analyzer. Clin. Chem. Acta., 73: 407-407.
21. Edmison, J. and A.J. McCullough, 2007. Pathogenesis of non-alchoholic steatohepatitis: Human data. Clin. Liver Dis., 11: 75-104.
22. Eiris, J., M.I. Novo-Rodriguez, M. Del-Rio, P. Meseguer, M.C. Del-Rio and M. Castro-Gago, 2000. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res., 41: 1-7.
23. Erns, J.M., S. Lojo, M.C. Del-Rio, I. Novo, M. Bravo, P. Pavonand, M. Castro-Gago, 1995. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology, 45: 1155-1157.
24. Engel, J. and International League Against Epilepsy (ILAE), 2001. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE task force on classification and terminology. Epilepsia, 42: 796-803.
25. Fichsel, H., 1980. Effects of different anticonvulsive drugs on liver enzymes. Acta Neurol. Scand, 62: 108-108.
26. Fishbein, M., F. Castro, S. Cheruku, S. Jain, B. Webb, T. Gleason and W.R. Stevens, 2005. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis and ultrasound. J. Clin. Gastroenterol., 39: 619-625.
27. Franzoni, E., M. Govoni, S. D'Addato, S. Gualandi, Z. Sangiorgi, G.C. Descovichand, G.P. Salvioli, 1992. Total cholesterol, high-density lipoprotein cholesterol and triglycerides in children receiving antiepileptic drugs. Epilepsia, 33: 932-935.
28. Gastaldelli, A., M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi, A. Mitrakou and B. Balkau, 2009. Fatty liver is associated with insulin resistance, risk of coronary heart disease and early atherosclerosis in a large European population. Hepatology, 49: 1537-1544.
29. Haque, M. and A. Sanyal, 2002. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol., 16: 709-731.
30. Isojarvi, J.I., T.J. Laatikainen, M. Knip, A.J. Pakarinen, K.T. Juntunen and W. Myllyla, 1996. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol, 39: 579-584.
31. Isojarvi, J.I., J. Rattya, V.V. Myllyla, M. Knip and R. Koivunene et al, 1998. Valproate, lamotrigine and insulin mediated risks in women with epilepsy. Ann. Neurol, 43: 446-451.
32. Johannessen, C.U., 2000. Mechanisms of action of valproate: A commentatory. Neurochem. Intern., 37: 103-110.
33. Kelishadi, R., S.R. Cook., A. Adibi, Z. Faghihimani and S. Ghatrehsamani et al, 2009. Association of the components of the metabolic syndrome with nonalcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol. Metab. Syndr., 1: 29-29.
34. Keskin, M., S. Kurtoglu, M. Kendirci, M.E. Atabek and C. Yazici, 2005. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics, 115: 500-503.
35. Khashab, M.A., S. Liangpunsakul and N. Chalasani, 2008. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr. Gastroenterol. Rep., 10: 73-80.
36. Kocak, N., A. Yuce, F. Gurakan and H. Ozen, 2000. Obesity: a cause of steatohepatitis in children. Am. J. Gastroenterol, 95: 1099-1100.
37. Kodama, Y., C.S. Ng, T.T. Wu, G.D. Ayers and S.A. Curley et al, 2007. Comparison of CT methods for determining the fat content of the liver. Am. J. Roentgenol, 188: 1307-1312.
38. Luef, G.J., M. Lechleitner, G. Bauer, E. Trinkaand, P. Hengster, 2003. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res., 55: 53-58.
39. Luef, G.J., M. Waldmann, W. Sturm, A. Naserand, E. Trinka et al, 2004. Valproate therapy and non-alcoholic fatty liver disease. Ann. Neurol, 55: 729-732.
40. Luoma, P.V., V.V. Myllyla and E. Hokkanen, 1982. Relationship between plasma high density lipoprotein cholesterol and anticonvulsant levels in epileptics. J. Cardiovasc. Pharmacol., 4: 1024-1027.
41. Mahajan, R, K. Gupta and V. Kapoor, 2010. A systematic account of pathogenesis, diagnosis and pharmacotherapy of metabolic syndrome: Things we need to know. Int. J. Pharmacol., 6: 338-345.
42. Manco M, G. Bottazzo, R. De-Vito, M. Marcellini, G. Mingrone and V. Nobili, 2008. Non alcoholic fatty liver disease in children. J. Am. Coll. Nu.tr., 27: 667-676.
43. McGowan, M.W., J.D. Artiss, D.R. Strandbergh and B. Zak, 1983. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem., 29: 538-542.
44. Mofrad, P., M.J. Contos, M. Haque, C. Sargeant and R.A. Fisher et al., 2003. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37: 1286-1292.
45. Mulhall, B.P., J.P. Ong and Z.M. Younossi, 2002. Non-alcoholic fatty liver disease: an overview. J. Gastroenterol. Hepatol, 17: 1136-1143.
46. NHBPEP, 2004. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics, 114: 555-576.
47. National Cholesterol Education Program (NCEP), 1994. National Cholesterol Education Program: Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics, 89: 495-501.
48. Nejad, S.E.M., M.R.A. Nikpour, F. Rahim, S.N. Naghibi and M.A. Bahrammi, 2009. A randomized open-label comparison of lamotrigine and valproate in patients with juvenile myoclonic epilepsy. Int. J. Pharmacol, 5: 313-318.
49. Nikalje, A.P.G., M. Ghodke and A. Girbane, 2011. GABA modulating agents: A brief review. Asian J. Biol. Sci., 4: 201-220.
50. Oliva, M.R., K.J. Mortele, E. Segatto, J.N. Glickman, S.M. Errurk, P.R. Ros and S.G. Silverman, 2006. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J. Comput. Assist. Tomogr., 30: 37-43.
51. Park, H.S., J.H. Han, K.M. Choi and S. Kim, 2005. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am. J. Clin Nutr., 82: 1046-1051.
52. Patton, H.M., C. Sirlm, C. Behling, M. Middleton, J.B. Schwimmer and J.E. Lavine, 2006. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J. Pediatr. Gastroenterol. Nutr., 43: 413-427.
53. Pylvanen, V., A. Pakarinen, M. Knip and J. Isojarvi, 2006. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav., 8: 643-648.
54. Pylvanen, V., M. Knip, A. Pakarinen, M. Kotila, J. Turkka and J.I. Isojarvi, 2002. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia, 43: 514-517.
55. Ramzan, M., I. Ali and A. Matin, 2009. Sonographic assessment of hepatic steatosis (fatty liver) in
56. Reaven, G., 2002. Metabolic syndrome. Pathophysiology and implication for management of cardiovascular disease. Circulation, 106: 286-288.
57. Rockall, A.G., S.A. Sohaib, D. Evans, G. Kaltsas and A.M. Isidori et al., 2003. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur. J. Endocrinol, 149: 543-548.
58. Ryan, C.K., L.A. Johnson, B.I. Germin and A. Marcos, 2002. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl, 8: 1114-1122.
59. Schindhelm, R.K., J.M. Dekker, G. Nijpels, L.M. Bouter, CD. Stehouwer, R.J. Heine and M. Diamant. 2007. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the hoorn study. Atherosclerosis, 191: 391-396.
60. Schwimmer, J.B., R. Deutsch, J.B. Rauch, C. Behling, R. Newbury and J.E. Lavine, 2003. Obesity, insulin resistance and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J. Pediatr., 143: 500-505.
61. Sonmez, F.M., E. Demir, A. Orem, S. Yildirmis, F. Orhan, A. Asian, and M. Topbas, 2006. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a) and liver enzymes. J. Child Neurol, 21: 70-74.
62. Szczepaniak, L.S., P. Nurenberg, D. Leonard, J.D. Browning and J.S. Reingold et al., 2002. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab., 288: 462-468.
63. Targher, G., L. Bertolini, R. Padovani, F. Poli and L. Scala et al, 2006. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J. Endocrinol. Invest., 29: 55-60.
64. Targher, G. and G. Arcaro, 2007. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 191: 235-240.
65. Tominaga, K., F. Fujimoto, K. Suzuki, M. Hayashi, M. Ichikawa and Y. Inaba, 2009. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance and waist circumference. Environ. Health Prev. Med., 14: 142-149.
66. Treeprasertsuk, S., F. Lopez-Jimenez and K.D. Lindor, 2011. Nonalcoholic fatty liver disease and the coronary artery. Dig. Dis. Sci., 56: 35-45.
67. Verrotti, A., S. Domizio, B. Angelozzi, G. Sabatino, G. Morgese and F. Chiarelli, 1997. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr. Child Health, 33: 242-245.
68. Verrotti, A., F. Basciani, M. De-Simone, D. Trotta, G. Morgese and F. Chiarelli, 2002. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J. ChildNeurol, 17: 265-268.
69. Verrotti, A., R. La-Torre, D. Trotta, A. Mohnand, F. Chiarelli, 2009. Valproate-induced insulin resistance and obesity in children. Horm. Res., 71: 125-131.
70. Verrotti, A., S. Agostinelli, P. Parisi, F. Chiarelli and G. Coppola, 2011. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav., 20: 382-385.
71. Volzke, H., D.M. Robinson, V. Kleine, R. Deutscher and W. Hoffmann et al, 2005. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J. Gastroenterol., 11: 1848-1853.
72. Vorum, H., L. Gram and B. Honore, 1993. Valproate and palmitate binding to serum albumin in valproate-treated patients, Relation to obesity. Epilepsy Res., 16: 55-64.
73. WHO, 2006. Who child growth standards: Length/height- forage, weight-for-age, weight-for-length, weight-for- height and body mass index-for-age. Methods and Development. Geneva, Switzerland, http://www.who. mt/childgrowth/standards.
74. Warmck, G.R., R.H. Knopp and V. Fitzpatrick, 1990. Estimating low density lipoprotein cholesterol by the friedwald equation is adequate for classifying patients on the basis of nationally recommended cut points. Clin Chem., 36: 15-19.
75. Wieckowska, A., A.J. McCullough and A.E. Feldstein, 2007. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology, 46: 582-589.
76. Yalcm, E., A. Hassanzadeh and K. Mawlud, 1997. The effects of long-term anticonvulsive treatment on serum lipid profile. Acta Paediatr. Jpn., 39: 342-345.
77. Zeitlhofer, J., A. Doppelbauer, G. Tribl, T. Leithaand, L. Deecke, 1993. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin. Invest, 71: 574-578.